Answer
Apr 01, 2026 - 08:25 AM
Yes, Rybelsus carries a boxed warning for thyroid C cell tumors, including medullary thyroid carcinoma (MTC), and is contraindicated in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Boxed warnings are the strongest safety warnings issued by the FDA and highlight risks that may be life-threatening. If you have any questions or concerns about the safety of this medication, please consult your healthcare provider for more information.
